ADITYA SINGH

Dr. ADITYA SINGH


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 January 2024 in Ageing Research Reviews
Verified
Journal Article
Closed access
SMShubhrat Maheshwari
Shubhrat Maheshwari
ASADITYA SINGH
ADITYA SINGH
VAVaseem Ahmad Ansari
Vaseem Ahmad Ansari
TMTarique Mahmood
Tarique Mahmood
RWRufaida Wasim
Rufaida Wasim
AVAmita Verma
Amita Verma

16 July 2025 in Medical Oncology
Verified
Journal Article
Closed access
PDF file
SMShubhrat Maheshwari
Shubhrat Maheshwari
ASADITYA SINGH
ADITYA SINGH
AVAmita Verma
Amita Verma
MSMohammad Shariq
Mohammad Shariq
JAJuber Akhtar
Juber Akhtar
Bhupendra G PrajapatiBhupendra G Prajapati
Bhupendra G Prajapati

25 July 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
RWRufaida Wasim
Rufaida Wasim
TMTarique Mahmood
Tarique Mahmood
MSMohd. Haris Siddiqui
Mohd. Haris Siddiqui
TWTanveer A. Wani
Tanveer A. Wani
SZSeema Zargar
Seema Zargar
MWMuhammad Wahajuddin
Muhammad Wahajuddin
Cardiovascular diseases are the major cause of death globally. Acute coronary syndrome is one of numerous cardiovascular illnesses, including advanced glycation end products (AGEs), which play an instrumental part in their development and progression. A substance with multiple pleiotropic characteristics is rosuvastatin. This study examined the cardioprotective effects of rosuvastatin in isoproterenol-induced myocardial injury, as well as the alterations in advanced glycation end products and their roles in cardiac damage. Rosuvastatin (10 mg/kg, orally) was given to male rats daily for 4 weeks, and on the 29th and 30th days, isoproterenol (85 mg/kg, subcutaneously) was administered to cause cardiac damage. Rats were euthanised on the 31st day, and various samples were collected for examination. Administration of isoproterenol increased cardiac mass, levels of cardiac damage markers, lipid oxidation, and collagen content in the heart. Additionally, it reduced the activities of SOD, CAT, GST, GR, and all other antioxidants. Additionally, isoproterenol raises levels of inflammatory markers including TNF-α and IL-6. It has been observed that advanced glycation end products rise along with heart injury. The AGE-RAGE cascade also messes with the injured heart’s echocardiogram. Additionally, histopathological alterations were noticed. According to the study, rosuvastatin has cardioprotective effects on the experimental model, which were supported by an array of physical, biochemical, and histological characteristics. Summary This study examined the cardioprotective effects of rosuvastatin in isoproterenol-induced myocardial injury, as well as the alterations in advanced glycation end products and their roles in cardiac damage. According to the study, rosuvastatin has cardioprotective effects on the experimental model, which were supported by a number of physiological, biochemical, and histological characteristics. By showing how the functional AGE/RAGE axis is inhibited following rosuvastatin medication, this work provides an etiologic theory involving rosuvastatin therapy in heart injury. These findings may also have practical significance since they highlight the intriguing possibility that rosuvastatin-induced modulation of AGE-RAGE signalling may represent a unique therapeutic approach for the prevention and treatment of other cardiovascular diseases.

19 August 2026 in Biomedical Materials & Devices
Verified
Journal Article
Closed access
PDF file
SMShubhrat Maheshwari
Shubhrat Maheshwari
ASADITYA SINGH
ADITYA SINGH
Jagat Pal YadavJagat Pal Yadav
Jagat Pal Yadav
AVAmita Verma
Amita Verma

22 July 2026 in Journal of The Egyptian Society of Nephrology and Transplantation
Verified
Journal Article
Open access
ASADITYA SINGH
ADITYA SINGH
SMShubhrat Maheshwari
Shubhrat Maheshwari
PKPavan Kumar
Pavan Kumar
MAMamta Agrahari
Mamta Agrahari
ASAkash Singh
Akash Singh
Diabetic nephropathy (DN) is a major complication of diabetes mellitus and a leading cause of chronic kidney disease and renal failure globally. This review comprehensively summarizes the pathophysiology, biomarkers, and therapeutic strategies of DN. Chronic hyperglycemia and dyslipidemia activate oxidative, inflammatory, fibrotic, and endothelial dysfunction pathways that drive disease progression. Key mediators such as advanced glycation end-products, transforming growth factor-β, protein kinase C, and the renin–angiotensin–aldosterone system contribute to glomerular injury, podocyte loss, and tubulointerstitial fibrosis. Emerging biomarkers, including Neutrophil gelatinase-associated lipocalin, Kidney injury molecule-1, N-acetyl-β-D-glucosaminidase, and podocyte-specific proteins, enable early detection and personalized management. Immune cells (macrophages, lymphocytes) and cytokines (tumor necrosis factor-alpha, interleukin-6, interleukin-18) further amplify renal inflammation and damage. Therapeutic interventions such as renin–angiotensin–aldosterone system blockers, sodium-glucose cotransporter-2 inhibitors, and anti-inflammatory or antioxidant agents demonstrate promise in delaying disease progression. This review also highlights recent insights into nanotechnology-based drug delivery and emerging molecular targets that could shape next-generation therapies for DN. Molecular and cellular mechanisms underlying diabetic nephropathy. Hyperglycemia induces oxidative stress, mitochondrial dysfunction, and activation of signaling pathways, including nuclear factor-κB, Janus kinase/signal transducer and activator of transcription, transforming growth factor-β, and protein kinase C. Crosstalk between mesangial, endothelial, and tubular epithelial cells promotes inflammation, extracellular matrix accumulation, and fibrosis.